The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
That was one of my questions, to try and get some news on additional potential products/income that they were actually allowed to answer. :-)
Warthog - it didn't drop 5% in the last hour of trading.
Amor - I've been wondering about this is a very vague way too, it's probably the future. AI is already well into the pharma space in various ways, including use of deep learning to help detect cancer earlier, which could then mean earlier targeted TYK2 treatments etc too. The future of medicine will start to make our current medicine look antiquated quite quickly I think!
It's ambiguously worded but the word concern refers to what happens when other products are used, but it doesn't happen when using SDC-1801.
I claim no technical expertise but they're just saying that when SDC-1801 is used against the cytokine storm (over response from the immune system) it doesn't end up with the virus increasing its activity again. Whereas when anti-inflammatories are used to reduce the immune response they allow the virus to increase activity again, which is obviously not what you would want.
My mistake - it was in the previous results RNS re the in vivo, but it still sounds good to read again ;)
Sixth - I thought the in vivo study results were new too...?
Also love the sentence about 'ongoing partnering activities'.
Apt advice from the a r s technica website :-)
"Eli Lilly and Incyte have reported new data from an additional cohort of the Phase III COV-BARRIER clinical trial, demonstrating that baricitinib decreased mortality risk in Covid-19 patients on mechanical ventilation or extracorporeal membrane oxygenation (ECMO). The sub-study data from 101 adults revealed that baricitinib plus standard of care (SoC) led to 46% and 44% reduced mortality risk by day 28 and day 60, respectively, versus placebo plus SoC."
Taken from the following link if anyone's interested: https://www.pharmaceutical-technology.com/uncategorised/coronavirus-company-news-summary-lilly-incyte-report-positive-efficacy-data-for-baricitinib-against-severe-covid-19-alnylam-discontinues-development-of-rnai-therapy/
Zylo isn't saying it is good news! It's one of those ambiguous phrases, but I think he/she just means that the news about covid doesn't get any better as time goes on.
Interesting to see that Sanofi have just acquired a Biotech company in the US for $3.2bn.
https://european-biotechnology.com/up-to-date/latest-news/news/sanofi-snaps-up-mrna-partner-for-us32bn.html
Even if Boris doesn't have a strategy for the UK, it doesn't matter for sareum as there is a wider world urgent need for Covid therapeutics ASAP that isn't going anywhere quickly, and other governments/organisations with deep pockets and proven interest. The NYT reports this morning that deaths from Covid in Africa have increased 80% over the past few weeks, and in the US they're concerned about a simultaneous rise in Delta infections and cases of respiratory syncytial virus among children.
I just watched a webinar about 'where we are currently with Long Covid' by the researchers behind the ZOE app, and it's disappointing to know more about possible therapeutics than the experts ;-) They said how great Dexamethasone is for treatment but has side effects, so should be limited in use for that reason, whereupon steam came out of my keyboard as I furiously typed out repeated comments about SDC-1801 being better, and without the tox issues. So if we see a surge in buying this afternoon I'll take full credit! :-)
Matador - Thoth has said that the SP will reach 17p by end of July, in the month of the re-rate.
We're all rooting for you to be right!
I thought they were probably your ISA Bailiff!
Good to see that the Director of the National Institutes of Health (appointed by Obama) has chosen to write about the Genome study detailed in the Nature article in his Director's Blog yesterday - more exposure for TYK2 on the world stage.
https://directorsblog.nih.gov/tag/tyk2/
Sareum's agenda - creating, developing and pushing forward potentially world-changing products in auto-immune, cancer & Covid-19, whilst also negotiating private funding to do so.
Trrime - who TF knows or cares?!
Today 11:37
"Afham3 It takes a man to admit when he is wrong and I think I jumped the gun a bit, read the RNS now 3 times, and I like it sorry guy's but there you go."
Today 12:25
"and its only £1m hardly earth shattering"
Afham - yeah I was reading it in an excited hurry! :) However, we now have two HNWIs with deep pockets - even better!
Or you could say that there is a HNWI who is both very confident in what they know of Sareum, and happy to help fund it. That is factual, as opposed to your tedious negative speculation.